Researchers, through testing, found the antibiotic to be very effective against E. coli, and carbapenem-resistant Enterobacter cloacae. It was effective against Mycobacterium bovis as well.
Estimating the value of interventions to reduce antibiotic use requires predictions of future levels of antibiotic resistance. However, modeling the trajectory of antibiotic resistance, and how marginal changes in antibiotic consumption contribute to resistance, is complex.
Researchers have identified a cluster of four patients harboring Escherichia coli carrying a rare antibiotic resistance gene, mcr-1. That gene renders the microbe resistant to colistin, an antibiotic of last resort. Three of those patients showed no symptoms, raising the risk of spread.
Researchers analyzed antibiotic resistance genes in urban wastewater collected at wastewater treatment plants in seven European countries and found that the amount of resistance genes was higher in the wastewater from countries with higher antibiotic use.
These data suggest that increased use of antibiotics in specific geographical areas is associated with an increased personal risk of acquiring antibiotic-resistant bacteria, independent of personal history of antibiotic consumption and other known risk factors for antimicrobial resistance.
Clinical microbiology has long relied on growing bacteria in culture to determine antimicrobial susceptibility profiles, but the use of whole-genome sequencing for antibiotic susceptibility testing is now a powerful alternative.
The London School of Hygiene & Tropical Medicine Antimicrobial Resistance Center, together with the MARCH and Malaria Centres will jointly host the Mass Drug Administration and Antimicrobial Resistance Symposium on 20 February 2019 in London, UK and by live stream. This symposium will bring together academics from a range of relevant disciplines to discuss the state of evidence, and draw out a future integrated research agenda that addresses potential hurdles with this approach, including concerns about antimicrobial resistance.
The US National Biodefense Strategy, released last year, highlights the need to reduce the emergence and spread of superbugs both domestically and internationally, and accelerate the development of new drugs, diagnostic tests, and vaccines.
Researchers developed a genome-scale metabolic network reconstruction of Chromobacterium violaceum and translated it into a mathematical model. A technique called constraints-based flux balance modeling is then used to compute cell function/phenotype. These methods are scalable and can be extended to any infection causing pathogen.
Host-directed therapy can boost a patient’s immune response instead of relying only on antibiotics.